Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, et al. Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial. Eur J Cancer 2025;231:116051.
PMID: 41207182